Latest news and upcoming events
SparingVision Presents Three Posters at the Association for Research in Vision and Ophthalmology (ARVO) 2021 Annual Meeting
SparingVision has presented three posters highlighting the Company’s recent research into ocular diseases and its lead gene therapy treatment, SPVN06.
Cytoki Pharma raises $45 million Series A financing
Ysios Capital joins 38 million euro Series A financing of Cytoki.
Aura Biosciences Presents New Preclinical AU-011 Data at the Association for Research in Vision and Ophthalmology (ARVO) 2021 Annual Meeting
AU-011 Demonstrates Targeted Cytotoxicity In Vitro and In Vivo in Both Breast and Lung Tumors.
Adcendo raises EUR 51 Million in Series A Financing to Advance Novel Antibody-Drug Conjugates for Treatment of Cancers
Ysios Capital co-leads EUR 51 million Series A financing in Adcendo.
Synendos Therapeutics Expands Series A to CHF 24 million with new investment
Ysios Capital joins existing syndicate of European investors.
SparingVision Expands Novel Ocular Disease Pipeline with Acquisition of GAMUT Therapeutics
Broadens SparingVision’s innovative genomic medicine pipeline to address both mid and late stages of rod-cone dystrophies with the added potential to combine both products.
Aura Biosciences Announces Publication of Data in Cancer Immunology Research Supporting the Immune Mediated Mechanism of Action of the Virus-Like Drug Conjugate (VDC) Technology Platform
Results Support VDCs induction of Pro Immunogenic Cell Death and the Generation of Long Lasting Adaptive Anti-Tumor Immunity
Mirum Pharmaceuticals and Vivet Therapeutics enter into exclusive worldwide option and license agreement for Vivet’s gene therapy programs targeting PFIC
Vivet to lead pre-clinical development of its two gene therapy programs for PFIC3 and PFIC2.
Minoryx Phase 2/3 ‘ADVANCE’ study results to be presented at the 2021 American Neurological Association (AAN) Annual Meeting
Overall results support the positive effects of leriglitazone on reducing the progression of cerebral lesions and myelopathy symptoms.
LAVA Therapeutics Announces Pricing of Initial Public Offering
Gross proceeds of the offering, before deducting underwriting discounts and commissions and other offering expenses payable by LAVA, are expected to be $100.5 million.
Subscribe to our weekly newsletter for the latest
updates on life sciences investments.